- Home
- KURA
KURA
Kura Oncology Inc.
as 05-23-2025 4:00pm EST
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 492.9M | IPO Year: | N/A |
| Target Price: | $24.50 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.41 - $23.48 | Next Earning Date: | 05-01-2025 |
| Revenue: | $67,991,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 171.9% | Revenue Growth (next year): | 60.51% |
Stock Insider Trading Activity of Kura Oncology Inc. (KURA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bair Teresa Brophy | KURA | Chief Legal Officer | May 19 '25 | Sell | $5.96 | 1,559 | $9,291.64 | 107,948 | |
| FORD KATHLEEN | KURA | Chief Operating Officer | May 19 '25 | Sell | $6.28 | 1,558 | $9,777.38 | 21,367 | |
| Hasnain Faheem | KURA | Director | Mar 21 '25 | Sell | $8.00 | 22,682 | $181,456.00 | 23,983 |
Latest Kura Oncology Inc. News
KURA Breaking Stock News: Dive into KURA Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025
GlobeNewswire
3 days ago
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
GlobeNewswire
6 days ago
Kura Oncology to Participate in Three Upcoming Investor Conferences
GlobeNewswire
11 days ago
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
GlobeNewswire
20 days ago
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
Thomson Reuters StreetEvents
23 days ago
Q1 2025 Kura Oncology Inc Earnings Call
GlobeNewswire
24 days ago
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GuruFocus.com
24 days ago
Kura Oncology Inc (KURA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Costs
Compare KURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KURA Kura Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.